The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2021

The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis

Résumé

Chordomas are rare sarcomas that are usually treated by surgery and/or radiotherapy since these are chemo-resistant tumors, but immunotherapy could be a possible option for chordoma patients. However, few reports investigating the composition of the chordoma immune microenvironment exist. We immunohistochemically studied 81 chordomas regarding their immune microenvironment factors and compared them with clinicopathological data. Macrophages and CD4 cells were the most prominent inflammatory cell populations, followed by CD8 T cells, while CD20 B cells and high endothelial venules (MECA-79+) were less frequently found. PD-L1 (22C3) expression by inflammatory cells was found in 21 (26%) tumors and was associated with a larger tumor size. None of the cases showed the expression of PD-L1 by tumor cells. Survival analysis showed that younger patients had a better overall survival. Considering the immunohistochemical factors studied, higher CD8, the presence of PD-L1+ immune cells, and higher vascular density were adverse prognostic factors, but in multivariate analysis, only PD-L1+ immune cells retained prognostic significance. To conclude, chordoma tumor cells do not express PD-L1, but PD-L1+ immune cells seem to play a negative prognostic role, supporting the need for further studies in this field and the possible beneficial role of immunotherapy in these patients.

Dates et versions

hal-03706795 , version 1 (28-06-2022)

Identifiants

Citer

Maroa Dridi, Lila Krebs-Drouot, David Meyronet, Jean Marc Dumollard, François Vassal, et al.. The Immune Microenvironment of Chordomas: An Immunohistochemical Analysis. Cancers, 2021, 13 (13), pp.3335. ⟨10.3390/cancers13133335⟩. ⟨hal-03706795⟩
8 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More